• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

Omega-3 polyunsaturated fatty acids linked to lower mortality from coronary heart disease

byJames EnglandandAnees Daud
June 29, 2016
in Cardiology, Chronic Disease, Public Health
Reading Time: 2 mins read
FDA-approved weight loss medications associated with weight loss at one year
Share on FacebookShare on Twitter

1. Biomarkers for omega-3 polyunsaturated fatty acid (omega-3 PUFA) levels were linked to lower mortality from coronary heart disease (CHD) in patients without prior known history of CHD.

2. Higher levels of docosapentaenoic acid (DPA), an omega-3 PUFA, was associated with lower risk of total CHD, but other markers, including eicosapentaenoic acid (EPA), docosahexaneoic acid (DHA), and a-linolenic acid (ALA), had no observable effect on total CHD risk.

Evidence Rating Level: 2 (Good)

Study Rundown: The role of diet-derived omega-3 PUFA in protection from morbidity and mortality associated with cardiovascular disease remains controversial. While some experimental studies have reported protective effects, randomized trials of fish oil supplements in those with CHD have failed to demonstrate significant effect. This study sought to evaluate the association between biomarkers representative of seafood- and plant-derived omega-3 PUFA and the risk of CHD in patients without prior history of significant CHD.

This global consortium of 19 studies evaluated the following omega-3 PUFA markers: eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), docosahexaneoic acid (DHA), and a-linolenic acid (ALA). Analysis was controlled for confounders such as age, sex, race, diabetes, and medications (including statins and aspirin). ALA, DPA, and DHA were associated with lower risk of fatal CHD, and DPA was associated with lower risk of total CHD. No observed effect on nonfatal MI was observed. The strengths of the study included the pooled data across many geographic locations and racial backgrounds. The utilization of biomarkers for ω-3 PUFA helped to accurately capture stable feeding habits, but they may have merely been markers of general healthy eating and not directly responsible for the improved outcomes.

Click to read the study, published today in JAMA Internal Medicine

RELATED REPORTS

Artificial intelligence (AI)-based coronary calcium quantification successfully identified patients who could benefit from lipid-lowering therapy

Higher maternal body mass index is associated with increased risk of cardiovascular disease in offspring

2MM: AI Roundup: NHS England expands Microsoft Copilot nationwide, ARPA-H advances autonomous cardiovascular AI, FDA advisors back Moderna’s mRNA influenza vaccine, and UpDoc earns first clearance for a patient-facing large language model

Relevant Reading: Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events

In-Depth [meta-analysis]: This study included 19 studies from a global consortium investigating dietary omega-3 PUFA through the use of biomarkers. There were 16 countries involved and 45 637 total participants without prior CHD. Biomarkers included EPA, DPA, DHA, and ALA from plasma, plasma phospholipid, cholesterol esters, or adipose tissue. CHD included fatal or non-fatal MI, sudden cardiac death, with total CHD and fatal CHD included in analysis. Covariates evaluated included age, sex, race, body mass index, educational level, smoking status, physical activity, alcohol use, diabetes mellitus, hypertension, aspirin use, and hypercholesterolemia.

In continuous variable analysis (per 1-SD increase) there was a ~9% lower risk of fatal CHD for each ω-3 PUFA with the relative risk for EPA of 0.91 (95%CI 0.82-1.00), DPA 0.90 (95%CI 0.85-0.96), DHA 0.90 (95%CI 0.84-0.96), and ALA 0.91 (95%CI 0.84-0.98). DPA levels were associated with lower risk of total CHD with relative risk 0.94 (95%CI 0.90-0.99). None of the biomarker levels were associated with changes in non-fatal MI risk.

Image: CC/Wiki

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascular diseasecoronary artery disease (CAD)omega fatty acids
Previous Post

Responsive Parenting intervention linked to improved infant bedtime routines

Next Post

Among sepsis survivors, primary care interventions not associated with improved mental health outcomes

RelatedReports

Artificial Intelligence

Artificial intelligence (AI)-based coronary calcium quantification successfully identified patients who could benefit from lipid-lowering therapy

September 15, 2026
Behavioral dysregulation in infancy predicts later child mental health
Cardiology

Higher maternal body mass index is associated with increased risk of cardiovascular disease in offspring

September 12, 2026
Collage of medical tech icons circling a central chip with 'AI Roundup' title and 2 Minute Medicine logo in teal background.
AI Roundup

2MM: AI Roundup: NHS England expands Microsoft Copilot nationwide, ARPA-H advances autonomous cardiovascular AI, FDA advisors back Moderna’s mRNA influenza vaccine, and UpDoc earns first clearance for a patient-facing large language model

September 3, 2026
Jessica Lau
Psychiatry

WHO launches 2026 global initiative to bridge the schizophrenia mortality gap

September 4, 2026
Next Post
Corticosteroids improve outcomes in treatment of community-acquired pneumonia

Among sepsis survivors, primary care interventions not associated with improved mental health outcomes

Reduced gestational weight gain with lifestyle intervention

Rehabilitation beneficial for patients with respiratory failure

ACE-inhibitor use associated with decreased conduction system disease

ACE-inhibitor use associated with decreased conduction system disease

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Prognostic associations of anthropometric indices vary by clinical outcomes
  • Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma
  • Gene therapy shows sustained benefit in Wiskott–Aldrich syndrome
License Content
Terms of Use | Disclaimer
Cookie Policy
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.